156 related articles for article (PubMed ID: 34909837)
1. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan.
Raza MN; Sughra K; Zeeshan N; Anwar MZ; Shahzad MA; Rashid U; Afroz A; Munir H
Braz J Biol; 2021; 83():e252610. PubMed ID: 34909837
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Treatment of Untypable HCV Variants in Different Districts of Punjab, Pakistan.
Zafar A; Imran M; Zahoor S; Shah ZH; Ali M; Afzal MS
Viral Immunol; 2018; 31(6):426-432. PubMed ID: 29920175
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan.
Afzal MS
Viral Immunol; 2017 May; 30(4):252-257. PubMed ID: 28118096
[TBL] [Abstract][Full Text] [Related]
4. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature.
Haqqi A; Munir R; Khalid M; Khurram M; Zaid M; Ali M; Shah ZH; Ahmed H; Afzal MS
Viral Immunol; 2019 Nov; 32(9):402-413. PubMed ID: 31556811
[TBL] [Abstract][Full Text] [Related]
8. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
Gill U; Aziz H; Gill ML
Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
[TBL] [Abstract][Full Text] [Related]
9. Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
Honma Y; Shibata M; Morino K; Koya Y; Hayashi T; Ogino N; Kusanaga M; Oe S; Miyagawa K; Abe S; Tabaru A; Harada M
Dig Dis Sci; 2023 Feb; 68(2):685-698. PubMed ID: 36100828
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
[TBL] [Abstract][Full Text] [Related]
12. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Alsaran K; Sabry A; Shaheen N
Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
[TBL] [Abstract][Full Text] [Related]
14. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
16. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
Aziz H; Gil ML; Waheed Y; Adeeb U; Raza A; Bilal I; Athar MA
Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487
[TBL] [Abstract][Full Text] [Related]
18. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
Akhan SC; Gurel E; Sayan M
Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report.
Knapstein J; Wörns MA; Galle PR; Zimmermann T
J Med Case Rep; 2014 Jul; 8():257. PubMed ID: 25047566
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.
Ali M; Afzal S; Zia A; Hassan A; Khalil AT; Ovais M; Shinwari ZK; Idrees M
Medicine (Baltimore); 2016 Dec; 95(50):e5327. PubMed ID: 27977575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
